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High titer autoantibodies produced by B lymphocytes are clinically important features of 
many common autoimmune diseases. APECED patients with deficient autoimmune regu-
lator (AIRE) gene collectively display a broad repertoire of high titer autoantibodies, including 
some which are pathognomonic for major autoimmune diseases. AIRE deficiency severely 
reduces thymic expression of gene-products ordinarily restricted to discrete peripheral 
tissues, and developing T cells reactive to those gene-products are not inactivated during 
their development. However, the extent of the autoantibody repertoire in APECED and 
its relation to thymic expression of self-antigens are unclear. We here undertook a broad 
protein array approach to assess autoantibody repertoire in APECED patients. Our results 
show that in addition to shared autoantigen reactivities, APECED patients display high 
inter-individual variation in their autoantigen profiles, which collectively are enriched in evo-
lutionarily conserved, cytosolic and nuclear phosphoproteins. The APECED autoantigens 
have two major origins; proteins expressed in thymic medullary epithelial cells and proteins 
expressed in lymphoid cells. These findings support the hypothesis that specific protein 
properties strongly contribute to the etiology of B cell autoimmunity.
Keywords: autoimmune regulator, autoantibodies, immune tolerance, thymus, autoantigen
inTrODUcTiOn
Many severe multifactorial autoimmune diseases are in part defined by pathognomonic antibod-
ies that provide important clinical tests of disease predisposition or status. However, whereas our 
knowledge of the genetic and cellular factors contributing to multifactorial autoimmune diseases is 
increasing, we remain largely ignorant of properties of autoantigens and why only selected proteins 
are targeted in autoimmunity (1). To investigate B cell autoantibody repertoire, we have examined 
APECED (autoimmune polyendocrinopathy with candidiasis and ectodermal dysplasia) patients 
(2), defined by rare monogenic defects in the autoimmune regulator (AIRE) gene that drives the 
expression of tissue-restricted self-antigens in medullary thymic epithelial cells (mTEC) (3–5). T cell 
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progenitors with strong reactivity toward such self-antigens are 
eliminated or functionally inactivated. Lacking AIRE function, 
APECED patients predictably accumulate many autoreactive 
T cells, but in addition they collectively display high titer autoan-
tibodies to multiple self-proteins (2).
The antibodies with the highest reported titers target type I 
interferons (IFNs) and have become diagnostic or even prognos-
tic markers for APECED (6). Neutralizing type I IFN antibodies 
mostly appear early in life (7), inhibit IFN-stimulated gene expres-
sion (8), and were recently shown to correlate inversely with the 
onset of type 1 diabetes (T1D) in APECED (9). A second group 
of APECED-associated autoantibodies targets Th17-associated 
cytokines, IL17A, IL17F, and IL22, emerges early in the disease 
course (7), and is associated with chronic mucocutaneous candidi-
asis (10, 11), another defining feature of APECED. Interestingly, 
our in-depth studies of anti-cytokine antibodies harbored by 
APECED patients showed that the functionally rearranged 
immunoglobulin gene sequences were heavily mutated, encod-
ing antibodies of extremely high affinity that we hypothesized to 
result from B cell dysregulation in germinal center reactions (9). 
Such etiology can be contrasted with the amplification and matu-
ration of natural, polyreactive autoantibodies that are normally 
of relatively low affinity, which has been proposed to underpin 
sporadic autoreactivity in otherwise healthy individuals (12).
There is a prominent set of APECED-associated autoantibod-
ies that are shared with multifactorial autoimmune diseases, such 
as those directed against glutamic acid decarboxylase (GAD)1 
and GAD2 in T1D (13), or against CYP21A2 in Addison’s disease 
(14). Therefore, the comprehensive analysis of autoantibodies in 
APECED may offer improved insight into the etiology of such 
diseases. These autoantibodies have often been identified by 
candidate or cDNA expression library screenings. However, pro-
teome arrays provide unprecedentedly broad coverage to identify 
novel target proteins, such as melanoma MAGEB antigens and 
testis-specific PDILT, which were recently identified as autoanti-
gens in APECED (15).
To gain further insight, we searched common features of autoan-
tigenic proteins by a systematic analysis of a protein microarray plat-
form, which allows large-scale, unbiased screening of autoantibody 
reactivities. Herein, we report a broad spectrum of autoantigens 
that is collectively targeted by 82 APECED patients. This APECED 
“autoimmunome” is not a random collection of proteins but 
comprises two sub-groups, those whose expression is most likely 
AIRE-regulated in the thymus and those enriched in lymphoid 
tissue. Moreover, these autoantigens are enriched in evolutionarily 
conserved cytosolic and nuclear proteins with high propensity for 
post-translational modifications. Reactivity to an increased number 
of such autoantigens was a stronger correlate of clinical symptoms 
than was either patient age or time since disease onset.
MaTerials anD MeThODs
Patient samples
Altogether 100 sera samples from 82 individual patients were 
profiled in Protoarray, as described (9). For longitudinal analysis, 
we collected 2 samples from 11 patients; 3 samples from 2 patients; 
and 4 samples from 1 APECED patient. Only one serum sample 
(with maximal number of positive hits) per patient was used in all 
analyses, except in longitudinal analysis where multiple samples 
taken at different time points were available from 14 patients. The 
patients were from Finland, Italy, Norway, Slovenia, and Estonia 
and diagnosed according to mutational analysis of the AIRE 
gene and by the presence of autoantibodies to type I IFNs. The 
mean age of the patients was 31 years. The main characteristics 
of the patients are given in Table S1 in Supplementary Material. 
The control group consisted of 20 individuals (12 healthy volun-
teers and 8 healthy first-degree relatives of the Italian APECED 
patient cohort). The study was carried out in accordance with 
the recommendations of local ethics committees (Finland: HUS 
Medical ERB, 8/13/03/01/2009; Slovenia: National Medical 
Ethics Committee number 22/09/09 and 28/02/13; Italy: Ethics 
Committee Prot. PG/2015/20440; Norway: Research Ethics 
Committee of Western Norway, health registry number 047.96, 
bio-bank number 2013-1504, project number 2012/1850; 
Estonia: Research Ethics Committee of the University of Tartu, 
235/M-23) with written informed consent from all subjects, as 
described earlier (9). All subjects gave written informed consent 
in accordance with the Declaration of Helsinki.
Protein array screening
The autoantibody screening was performed by ISO9001 certi-
fied Custom ProtoArray Service Lab at Invitrogen (Thermo 
Fisher Scientific). Briefly, the protein arrays (ProtoArray v5.1) 
were probed as described in Invitrogen’s protocol for Immune 
Response BioMarker Profiling using detection reagent (Alexa 
Fluor 647 Goat Anti-Human IgG A21445, Invitrogen) and 
blocking buffer (Blocking Buffer Kit PA055, Invitrogen). Arrays 
were scanned using a GenePix 4000B fluorescent scanner, and the 
data were acquired with GenePix® Pro software. The arrays were 
probed with sera at a dilution of 1:500.
Data cleaning, normalization, and  
Print contamination
Previous studies involving protein microarrays (16) have shown 
that raw intensity values should not be compared directly because 
of technical, physical, chemical, and individual variability, occur-
ring mostly at the production stage. In order to preserve true 
biological signal and concurrently eliminate potential technical 
noise, we applied a robust linear model (RLM) approach (17), 
using rlm function in R. RLM is considered to be the state of the 
art normalization technique for protein microarray data (18) and 
is applied on control probes that are assumed to have constant 
positive signal across all arrays. We used human-IgG and V5 
control series for normalization as reported (17). Background 
subtracted signal was log-transformed prior to applying RLM to 
approximate for normal distribution (Figure S1 in Supplementary 
Material). To address printing contamination, we excluded all 
autoantibody targets that showed high correlation (>0.6) with 
previously reported autoantigens. In addition, we identified and 
eliminated highly correlated proteins located in the neighboring 
wells on the array. In total, we identified and removed 31 false 
positives, some of which were prevalently positive across many 
samples (Figure S2 in Supplementary Material). The normalized 
signal was standardized using mean and SD of healthy samples 
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(including healthy heterozygous relatives). Proteins, with stand-
ardized signal (z-score) above 3 in three or more patients were 
regarded as autoantigens. The full list of the positive proteins is 
provided in Table S2 in Supplementary Material.
Differential Data analysis and  
clustering of autoantibody reactions
In order to identify the proteins correlating with various clini-
cal manifestations, we used moderated t-statistics implemented 
in ebayes function from limma R package (19) on normalized 
intensities from all 9,000 proteins. Obtained p-values were 
corrected using false discovery rate correction method and top 
significant proteins (corrected p-value <0.05) were extracted 
for each manifestation resulting in six significant associations. 
Unsupervised hierarchical clustering using pheatmap package 
in R, which internally uses hclust function for clustering rows 
and columns of matrix. Linear regression analysis of dependency 
between number of positive hits and number of manifestation 
was analyzed with lm method in R.
Variability of aPeceD autoantigen  
Profile over Time
We extracted data for 14 patients with multiple samples and 
formed all possible pairs of samples that belong to the same 
patients and divided these pairs into two broad categories: pairs 
of samples that were obtained >10  years apart (eight samples, 
on average 24.4  years apart) and samples that were obtained 
<10 years apart (13 samples, on average 1.5 years apart). Reactive 
proteins were compared between samples of the same patient and 
the percentage of the proteins that were specific to early, late, or 
shared between samples for both of the categories was computed. 
As expected, samples taken close in time had more reactive 
proteins in common, then samples obtained more than 10 years 
apart. Samples taken more than 10 years apart show higher per-
centage of late sample specific proteins, which might mean that 
with time repertoire of reactive proteins gets larger.
correlation with aPeceD Mutations
We divided the patients into three groups based on their muta-
tions: (1) homozygous for p.R139X, (2) homozygous for p.R257X, 
and (3) homozygous p.L323fsX373 or compound heterozygotes 
of either p.L323fsX373 or missense mutations. We used pairwise 
comparisons of Tukey and Kramer (Nemenyi) test with Tukey-
Dist approximation for independent samples.
The enrichment analyses for  
Protein characteristics
To assess intrinsic features of positive reactivities, we used data 
from the following public databases: Human Protein Atlas (20), 
Compartments DB (21), dbPTM (22), UniProt Knowledgebase 
(23), Ensembl (24), OrthoDB8 (25), and SUPERFAMILY (26). 
We used gconvert function from gProfileR package in R (27) 
to convert names of genes and proteins into Ensembl gene 
identifiers (ENSG). Size of the overlap between our group of 
positive proteins and every set extracted from each database 
was estimated. Using hypergeometric test for each overlap, 
we computed probability values to estimate how likely it was 
to observe this overlap or larger by random chance. We used 
false discovery rate procedure to adjust obtained p-values and 
significance threshold of 0.05 to reject a null-hypothesis. To 
double check our findings, we used g:Profiler web-tool (27) by 
submitting our list of positive proteins and running unordered 
query with ProtoArray content as a background to account for 
any design bias.
single nucleotide Polymorphism (snP) 
and evolutionary conservation analysis
For SNP analysis, we retrieved all SNPs associated with each 
gene on our platform that was found in Ensembl database 
(7,284 genes). To retrieve this information, we used R command 
useMart and the following parameters: useMart(“ENSEMBL_
MART_ENSEMBL”, dataset = ‘hsapiens_gene_ensembl’, 
host = “www.ensembl.org”). We then calculated the number of 
SNPs within boundaries of the gene and SNPs that are located 
at the exon regions of the gene. We normalized these values by 
associated gene length (distance between two furthest associ-
ated SNPs), by gene length, and by accumulative length exon 
regions of each gene, respectively. To compare positive proteins 
with the rest of platform in terms SNP counts, we first sampled 
10,000 random groups of genes of the same size as our group 
of reactive proteins. For each group, we computed mean counts 
of two categories. For evolutionary conservation analysis, 
the data were obtained from ftp://cegg.unige.ch/OrthoDB8/
Eukaryotes/. We downloaded four pairs of genes and annota-
tions for all_species, mammalia, metazoa, and vertebrata. In 
all four gene files, we filtered out genes not related to Homo 
sapiens and converted Ensemble protein IDs into gene IDs 
using biodbnet (http://biodbnet.abcc.ncifcrf.gov/db/db2db.
php) software. We calculated an average evolution rate for our 
group of reactive proteins (for all genes that had evolutionary 
rate recorded in DB). Then we sampled 10,000 random groups 
of the same size as our reactive group and calculated an average 
evolutionary rate.
luciferase immunoprecipitation  
(liPs) analysis
Luciferase immunoprecipitation assay was performed as reported 
(28, 29). Autoantigen cDNAs were cloned into modified pNa-
noluc vector (Promega, Madison, WI, USA) downstream of 
naturally secreted NanoLuc luciferase (Nluc). HEK293 cells were 
transfected with the plasmid constructs and cell culture medium 
containing Nluc-fusion proteins was collected after 48 h. Serum 
samples were first incubated with the fusion protein solutions 
overnight, then Protein G agarose beads were added and incu-
bated at room temperature for 1 h in 96-well microfilter plates 
(Merck Millipore, Billerica, MA, USA) to capture antibodies and 
immune complexes to the beads. After the washing to remove 
unbound fusion proteins, a luciferase substrate (furimazine) was 
added to reaction, and luminescence intensity (LU) was measured 
in Victor X Multilabel Plate Reader (PerkinElmer Life Sciences, 
Waltham, MA, USA). Results were expressed as relative units 
LU sample/average LU of healthy control samples. The positive/
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negative discrimination level was set to the mean plus three SDs 
of the healthy control samples.
resUlTs
Protoarray screening of aPeceD sera
The basis for our unbiased study of APECED autoreactivities 
was a protein microarray (Protoarray) of approximately 9,000 
proteins printed to a single glass slide. Against this array, we 
screened 100 sera from 82 patients of Finnish, Norwegian, 
Slovenian, Sardinian, and Estonian origins, together with control 
sera obtained from healthy heterozygous relatives (n = 8) and 
unrelated healthy controls (n = 12) across the same age range.
The arrays were normalized by RLM (17) based on control 
protein intensities with further standardization and limitation of 
false-positives (described in Materials and Methods). The posi-
tive proteins were defined as signals with a z-score (the number of 
standard deviations SDs from the mean of combined controls) of 
greater than 3 (which is more stringent than the common practice 
of calling hits at z > 2). Although APECED patients altogether 
displayed significantly different set of autoreactivities in com-
parison to controls, the reactivity profiles contained multiple 
patient-specific reactivities in addition to shared autoantibodies 
(9). Therefore, to intensify the likely biological and clinical signifi-
cance of hits, we considered a protein to be an autoantigen only 
when it was recognized by ≥3 individual patient samples (see 
Materials and Methods). When this additional stringency was 
applied, proteins encoded by 963 unique Refseq genes qualified 
as autoantigens.
autoantigen repertoire contains shared 
and individual reactivities
As expected, multiple sera displayed strong reactivities toward 
approximately 20 proteins that were previously reported as 
APECED autoantigens, including type I IFNs (Figure 1A), Th17 
cytokines, GAD1, GAD2, DDC, TGM4, GIF, HSD3B2, BPIFB1, 
TSGA10, CYP1A2, KCNRG, and AQP2 (Figure 1B). Moreover, 
most such reactivities were also detected by LIPS assay (Figure S1 
in Supplementary Material). It should be noted that apart of 
HSD3B2, the set of proteins on Protoarray did not include the 
steroidogenic enzymes CYP21A2, CYP17A1, and CYP11A1, 
which have been demonstrated as autoantigens in APECED.
Among shared reactivities, the highest titers were shown by 
interferon-α (IFNA)-specific antibodies, for which we identified 
some strong correlations (coefficients from 0.41 to 0.98), the 
highest being between IFNA2 and IFNA4 (correlation ~0.98), 
and IFNA6 and IFNA17 (correlation ~0.93) (Figure 1C). These 
correlations could not be explained by the levels of primary 
sequence similarity or by close phylogenetic relationships (Figure 
S2 in Supplementary Material), and are instead likely to reflect 
shared conformational epitopes in IFNA proteins. Likewise, 
there was commonly a strong correlation (coefficient from 0.41 
to 0.62) of IFNA reactivity with reactivity toward IFN-ω (IFNW) 
(Figure 1C).
In addition to shared reactivities, we found high inter-
individual variation in the number and identity of autoantigens 
(Figure  1D). To analyze a covariance of sample groups, we 
performed a principal component analysis, which showed that 
the relatively homogenous group of combined healthy relatives 
and control samples readily segregated from the patient samples 
that displayed a large intra-group variability (Figure 1E).
Multiple specificities include cancer–
Testis and Testis-specific autoantigens
Among the strong, “rare” specificities, there was a number of 
potential autoantigens depicted in Figure 2A. Of these, LCN1 
was reported as an autoantigen in Sjögren syndrome patients 
(30), and HMGB1 was reported to be associated with the pro-
duction of anti-DNA autoantibodies in systemic lupus erythe-
matosus (31). To extend the Protoarray results, we used LIPS to 
assay reactivity toward eight of these proteins (LCN1, MKNK2, 
POMZP3, BAALC, FGF12, HMGB1, RPL12, and S100A7A) 
of sera from a subgroup of 30 Finnish APECED patients 
(Figure 2B). The first three showed particularly strong positive 
correlations between Protoarray and LIPS results (Figure 2C), 
but given that the reactivities were often rare and that the patient 
groups tested in the two assays did not completely overlap, it 
was not surprising that correlations were not always statisti-
cally significant. Of note, however, this did not reflect a general 
tendency of the Protoarray to reveal false positives, since some 
sera showed much stronger LIPS reactivity to defined targets 
(e.g., RPL12, FGF12, HMGB1; Figure  2C). Indeed, this may 
reflect the potential of the Protoarray to underestimate reac-
tivities of conformation-specific autoantibodies, because of the 
denatured states of many of the arrayed proteins and protein 
fragments.
Interestingly, we noted reactivities toward ~20 so-called 
“cancer-testis autoantigens” (CT-As) (Figure 2D). CT-As can 
be expressed in a wide variety of malignant tumors, where they 
are known to be immunogenic, but their expression in normal 
tissue is mostly restricted to germ cells in testis, fetal ovary, and 
placenta (32). The extent of reactivity revealed by our screen 
far exceeded the previous report of shared APECED reactivity 
to CT-As PDILT and MAGEB2 (Figure  2D) in a large-scale 
screening of another APECED cohort (15). Rather, we found 
reactivities toward several proteins from the MAGE-A—
MAGE-B family that are expressed in melanoma and other 
tumor types but which in normal tissues are expressed only 
in the testis; reactivities toward GAGE1 and GAGE7B, which 
are members of another X-chromosome linked, CT-A family; 
and reactivities toward SPAG8 and SPAG16 (Figure 2D). The 
latter two in particular highlight the cross-over of APECED 
serum autoreactivities with other pathophysiologies, in that 
SPAG8 was initially identified as a sperm-associated antigen 
target of serum of an infertile woman (33), while SPAG16 is 
expressed in sperm and in reactive astrocytes of lesions in 
multiple sclerosis patients in whom it has been identified as 
an autoantibody target (34). Of note, both males and females 
showed autoreactivities toward several sperm-specific proteins 
(Figure 2E). Protoarray reactivities toward 11 testis specific and 
CT-antigens tested showed good overall correlation with LIPS 
(Figures 2E,F).
FigUre 1 | Protoarray reactivities to type I interferons (IFNs) and to known autoantigens. The reactivities to (a) type I IFNs and (B) known APECED autoantigens. 
The Protoarray signals are expressed as z-scores representing the number of SDs from the mean of combined control samples. Positive-negative discrimination 
level (dark red line) was set at z = 3. Red circles represent the samples with z > 3, gray circles are control samples. (c) Heatmap of correlation coefficients of type I 
IFN reactivities between each other. (D) Variation analysis of controls and patients—each dot on this figure represents a SD within sample over all Protoarray signals. 
Red circles represent patients (P) and black controls (C). Variance in patient samples are significantly higher (p = 2.598e−07) in comparison to control samples.  
(e) Principal component analysis plot of controls and patients. The first two principle components explain 35.8 and 11.5% of total variance, respectively. First 50 
most common autoantibody reactivities were used in order to build this plot.
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autoantibody correlations with clinical 
Manifestations
We next analyzed whether immunoreactivities to certain 
autoantigens correlated with disease components of individual 
APECED patients (Figure 3). Pernicious anemia correlated with 
seven reactivities, including gastrointestinal factor GIF that is an 
established autoantigen in pernicious anemia patients (35); five 
specificities, including GAD1 and GAD2, correlated with vitiligo; 
and autoantibodies to GABPB2 correlated with autoimmune 
hepatitis in APECED patients. By contrast, several associations 
described previously among small-scale studies, e.g., DDC 
with AIH and vitiligo (36, 37), were not revealed. In addition, 
we confirmed that reactivity toward prostate specific antigen, 
TGM4, was almost restricted to post-pubertal males (Figure S3 
in Supplementary Material) (38).
To test whether the autoantibody reactivities might segregate 
APECED patients into subgroups, we performed unsupervised 
hierarchical clustering of patients and the 50 most-reactive 
autoantigens, from which we excluded type I IFNs. This analysis 
clearly revealed two patient sub-groups with overall low and high 
reactivity repertoires, respectively (Figure 4A). An overlay of this 
heatmap with clinical data showed that the number of autoanti-
gens targeted was positively correlated with the number of clinical 
manifestations, as confirmed by linear regression (Figures 4B,C).
As the number of disease components in APECED patients 
is known to increase over time, we tested whether the number 
of autoantibody targets in each patient is likewise related to 
the age of onset of the first clinical manifestation. However, the 
trend toward correlation between the number of diseases and 
either age or time since diagnosis was not significant (Figure S4 
FigUre 2 | Autoantibody reactivities to selected novel autoantigens. (a) The Protoarray signals are expressed as z-scores representing the number of SDs from the 
mean of combined control samples. Positive–negative discrimination level (dark red line) was set at z = 3. Red circles represent the samples with z > 3, gray circles are 
control samples. (B) Seven out of the 29 novel autoantigens were tested in luciferase immunoprecipitation (LIPS) using a subset of 30 Finnish APECED patients’ 
samples. Red color in the cells of the heatmap represents positive reactivity (z > 3), gray cells indicate missing values and white color stands for missing autoantibodies. 
Rows on top indicate gender and age. (c) Correlation analysis of Protoarray and LIPS results on the autoantigens in panel (B). (D) z-Scores to 19 cancer–testis antigens 
(CT-As) in APECED patients according to Protoarray results coded as in panel (a). (e) Twelve of identified CT-As were retested using LIPS assay in a subset of 30 
Finnish APECED patients. Color code as in panel (B). (F) Correlation analysis of Protoarray and LIPS results of CT-As in panel (e). Color of dots and fitted linear trends in 
panels (c,F) represent the value of correlation coefficient, higher coefficient values are encoded as red color and low or negative correlation as blue.
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in Supplementary Material), arguing that neither can indepen-
dently explain the accumulation of multiple clinical entities 
in APECED. Instead, these findings add further weight to the 
conclusion that the complexity of the autoantibody response is 
a major underlying factor for the expansion of clinical profile in 
APECED.
Previous studies have shown changes in autoantibody pro-
files over time. To understand the dynamics of autoantibody 
FigUre 3 | Autoantibody reactivities associated with APECED patients clinical and phenotypic features. Association of Protoarray z-scores with corresponding 
clinical manifestations. The height of the bar depicts z-score of the sample, red bars represent samples positive for a given manifestation (indicated below each plot). 
All other bars in gray represent autoantibody levels in patient samples without the certain clinical manifestation. Only statistically significant associations are shown 
( p < 0.05) and adjusted across 900 most reactive proteins on Protoarray using moderated contrast t-test.
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repertoire, we studied 14 APECED patients whose sera were 
collected at least twice in different time points and, thus, ana-
lyzed longitudinally by Protoarray. In most patients (n = 11), the 
number of proteins recognized by autoantibodies increased with 
time (Figure 4D), whereas in only three patients the number of 
reactivities decreased or remained almost unchanged. We next 
studied whether the target antigen profile in APECED patients 
broadens over time. For this, we compared the samples taken less 
than 10 years apart with the samples spanning more than 10 years 
in three separate categories: (i) target specific to early sample, 
(ii) target shared in early and late sample, and (iii) target specific 
to late sample. Expectedly, the proportion of targets specific to 
late sample was larger indicating that the samples taken closer 
in time shared more reactivity to autoantigens than samples 
obtained more than 10 years apart (Figure 4E).
nature of aPeceD autoantigens
Of the many AIRE truncating mutations identified in APECED 
patients, the most prevalent are p.R257X creating a premature 
stop codon in exon 6, and a 13bp deletion, p.L323fsX373, 
changing the reading frame and causing a premature stop 
codon in exon 8. Although both mutations are present in 
APECED patients with various ethnic backgrounds, the R257X 
is commonly found among Finnish (83% of APECED alleles), 
Norwegian and Slovenian patients. By contrast, the earliest 
AIRE truncation occurs in Sardinian patients who share a 
p.R139X mutation that introduces a premature stop codon prior 
to the SAND domain (Sp100, AIRE-1, NucP41/75, DEAF-1), 
an ~80 residue region common to many chromatin-regulating 
factors. When we divided the patients into three groups based 
on these genetic etiologies [(1) homozygous for p.R139, (2) 
homozygous for p.R257X, and (3) homozygous p.L323fsX373, 
or compound heterozygotes of either p.L323fsX373 or missense 
mutations], we found patients in Groups 1 and 2 to react to a 
wider spectrum of autoantigens (Figure 5A), thereby correlat-
ing autoantibody reactivities with the p.R139X and p.R257X 
truncation mutations.
Intrinsic features of proteins that might promote their autoan-
tigenicity are not known. Indeed, the available information on 
the repertoire of autoantibody target proteins is fragmented, and 
based on this, few if any overt similarities have emerged among 
proteins identified as autoantigens. Given the scale of the analysis 
described here, we systematically analyzed our list of autoanti-
body target proteins for any parameters that might be enriched 
relative to proteins that were not targets (Figure 5B; Table S2 in 
Supplementary Material).
We first studied the subcellular localizations of APECED 
autoantigens by employing two different approaches: (i) the 
Compartments resource that integrates sequence-based and 
manually curated subcellular localization information from 
FigUre 4 | Continued
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FigUre 5 | Autoantibody correlation with APECED mutations and enrichment analysis for protein characteristics. (a) Correlation of the number of autoantibody targets 
with APECED mutations using pairwise comparisons with Tukey and Kramer (Nemenyi) test and Tukey-Dist approximation for independent samples. The first and the 
second mutation types are significantly different from the third type in terms of log2 of positive hits with p-values 0.0016 and 0.0072, respectively. (B) Association of 
autoantigens with different protein characteristics. Length of each bar is directly proportional to the significance of the term, calculated with hypergeometric test. False 
discovery rate was used to correct for multiple testing. Red line is drawn at 0.05 significance level. (c) Association of positive reactivities with tissue-specific gene 
groups from Human Protein Atlas. Hypergeometric test was used to compute displayed p-values and false discovery rate was used to correct for multiple testing.
FigUre 4 | Continued  
Characteristics of APECED patients and Protoarray reactivities. (a) Clustering patients and z-scores for the 50 most commonly recognized autoantigens using 
hierarchical clustering algorithm. (B) Clustering patients (columns) according to their clinical manifestations (rows). Red squares represent the presence of a given 
manifestation, while white and gray show absence of manifestation and missing information, respectively. (c) Positive correlation between the number of 
manifestations and the number of autoantigens (z > 3, logarithmized), correlation coefficient ~0.29. (D) Analysis of longitudinal serum samples taken at different time 
points. Blue squares and connecting lines (n = 11) correspond to samples with increased number of autoantigens and red squares and connecting lines (n = 3) 
correspond to samples with decreased or unchanged number of autoantigens. Each line and connected squares correspond to one APECED patient with samples 
collected at different time points. The locations of the squares on y-scale correspond to the age of the patient when the samples were collected. The sizes of the 
blue and red squares correspond to the number of positive autoantigens in corresponding samples. (e) The change of autoantigen profiles in samples collected 
longitudinally. The two columns show the autoantibody reactivities in patient samples taken less than 10 or more than 10 years apart. The autoantigens were 
compared between the samples of the same patient and divided into three categories according to their specificity: (i) specific to early sample, (ii) shared in early and 
late sample, and (iii) specific to late sample. The numbers in columns indicate the proportions of each category. Samples taken more than 10 years apart show 
higher percentage of autoantigens in the late samples, indicating that the autoantibody repertoire gets broader with time.
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PSORT and YLoc databases and (ii) g:Profiler that searches for 
a cellular component as one of the Gene Ontology categories 
(27). The majority of autoantigens were significantly associated 
with intracellular location (adj. p-values 2.62e−07 and 7.20e−03 
for Compartments and g:Profiler analysis, respectively), and in 
particular with either a cytosolic location (adj. p-values 6.04e−07 
and 3.01e−05 for Compartments and g:Profiler analysis, respec-
tively) or, to a lesser extent, a nuclear location (p = 0.0054) (Table 
S2 in Supplementary Material).
Posttranslational modifications have been proposed to 
contribute to autoimmune responses (39). Indeed, when we 
compared our database with dbPTM datasets (22) comprising 
an integrated resource for protein posttranslational modifica-
tions, we found that the autoantigens were strongly enriched 
in proteins with histidine/serine/threonine phosphorylation 
(adj. p =  3.34e−06 for HST). The association was significant 
even when threonine and serine phosphorylation were com-
pared separately (adj. p-value 4.22e−06 for threonine only and 
8.43e−04 for serine only). However, tyrosine phosphorylation 
alone was not enriched and adding tyrosine phosphorylation as 
a category to the accumulated list of phosphorylated proteins 
decreased the significance level. We searched for the enrichment 
FigUre 6 | Genetic polymorphisms and evolutionary conservation of APECED autoantigens. (a) Association of autoantigens with single nucleotide polymorphisms 
(SNPs). Two SNP categories were analyzed: the number of SNPs (i) within the boundaries of a gene (left histogram) and (ii) within exon regions of a gene (right 
histogram). For both histograms 10,000 randomly sampled groups of Protoarray proteins (genes) were generated with the size equal to the size of positive 
autoantigen group. On the x-axis the average number of SNPs is shown. The red dashed line shows the number of SNPs in positive autoantigen group. The p-value 
for each category of SNPs has been calculated in order to estimate the significance of a difference between randomly sampled groups and positive group. The 
autoantigen group has lower mean normalized SNP count, then it would be expected on average for the genes encoding proteins on Protoarray. (B) Evolutionary 
conservation rate. The four histograms that show distribution of average evolution rates for 10,000 randomly sampled groups of Protoarray genes were generated 
with the size equal to the size of positive autoantigen group. Each histogram represents a comparison of positive autoantigen group with ortholog genes in different 
evolutionary categories (all, metazoa, mammalia, or vertebrata species). On the x-axis the average evolutionary rate is shown. The red dashed line represents an 
average evolutionary rate of positive autoantigen group. Computed p-values indicate that autoantigens are on average more conserved in categories all and 
metazoa than the rest of the genes encoding proteins on Protoarray.
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of specific protein features in UniProtKB and Superfamily 
databases comprising a collection of protein function informa-
tion. This analysis surprisingly revealed that autoantigens were 
enriched for proteins from which the initiator methionine is 
processed by methionine aminopeptidases (adj. p  =  0.0070) 
and representation of proteins with DNA binding potential 
FigUre 7 | Medullary thymic epithelial cells (mTEC) specific expression of 
tissue-restricted (TR) APECED autoantigens. TR APECED autoantigens but 
not the non-tissue-restricted (NTR) autoantigens were upregulated in mature 
Aire-expressing mTECs. Datalists [generated by Sansom et al. (42)] of 
differentially expressed genes in mTEC subsets were compared to the list of 
APECED autoantigens. Strong enrichment of TR autoantigens was found 
among differentially upregulated genes in mature mTEC subpopulation in 
comparison to (i) immature mTECs, (ii) Aire-negative mTECs, and  
(iii) Aire-knockout mTEC populations. Blue circles mark the corresponding 
cell populations, the gradient in connecting lines indicate whether the genes 
in comparison were up- or downregulated, and the width of the lines 
represents the logarithmized p-value. No significant overlap was found 
among NTR autoantigens differentially expressed in any of the studied thymic 
cell comparisons.
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(adj. p =  0.0091) (Supplementary Table S2 in Supplementary 
Material).
The genes encoding autoantigens have been suggested to be 
enriched for SNPs (40). However, when we studied SNP data 
from Ensembl.org, the genes encoding APECED autoantigens 
displayed fewer SNPs in their gene regions (p = 0.0126) as well 
as in exons (p = 0.0592) (Figure 6A). To study how evolutionary 
conserved the APECED autoantigen gene families (41) are, we 
used OrthoDB8 database to retrieve the calculated evolutionary 
rates of the autoantigen genes (as human counterparts) against 
ortholog genes in four different taxonomic levels (all species, 
metazoan, vertebrata, and mammalian species). We found that 
the genes encoding APECED autoantigens showed significant 
association with the two conserved taxonomic levels (all species, 
p =  0.0225; metazoan species, p =  0.024; and a similar trend 
in mammalian and vertebrata species categories) (Figure  6B) 
indicating an evolutionary conserved nature of APECED autoan-
tigens. Thus, in comparison to all genes in the genome, APECED 
autoantigen genes have less genetic polymorphisms and are more 
conserved in evolution.
autoantigens segregate Based on mTec 
expression and aire Dependence
The key role of AIRE is considered to be the establishment of 
tolerance toward proteins restricted to discrete peripheral tis-
sues, the so-called tissue-restricted (TR) antigens. However, 
unexpectedly, we did not find the APECED autoimmunome to 
be appreciably enriched in TR antigens. In fact, when each tissue 
was analyzed separately using the Human Protein Atlas database 
(20), the APECED autoantigens showed the strongest significant 
correlation with gene expression in lymphoid tissues, specifically 
tonsils, spleen, appendix, and lymph nodes (Figure 5C; Table S2 
in Supplementary Material).
These findings notwithstanding, given that AIRE is the 
driving cause of APECED, we hypothesized that the autoan-
tibody repertoire might target two components: TR antigens 
and non-tissue-restricted (NTR) antigens enriched in AIRE-
independent lymphoid tissue proteins. To test this hypothesis, 
we divided the genes encoding the autoantigens according to 
their TR or NTR expression pattern (Table S2 in Supplementary 
Material). We then cross-referenced mouse databases on 
the expression of genes by mature mTECs and to its subsets, 
including those where thymic AIRE expression is limited or 
lacking by knockout approach (42) (note the necessity to use 
mouse databases reflected by the lack of comprehensive human 
thymus gene expression data). Having converted human gene 
accession numbers to mouse counterparts, we found a very 
strong overlap of genes encoding APECED TR autoantigens 
with genes more highly expressed in mature mTEC compared to 
two Aire-negative subsets: immature mTEC (p = 0.00022) and 
Aire-negative mTEC subpopulation (p =  0.00016) (Figure  7). 
The genes downregulated in Aire-deficient mTEC cells were 
likewise enriched in genes encoding APECED TR autoantigens 
(p =  0.00022). By contrast, the NTR group showed no such 
correlations. Furthermore, the NTR group was associated even 
more strongly with intracellular phosphoproteins, expressed in 
lymphoid tissues.
DiscUssiOn
Our profiling of APECED autoantibody reactivities yielded a 
broad autoantibody repertoire and, except type I IFN and Th17 
related cytokines, remarkable inter-individual variability. The 
number of candidate autoantigens ranged to almost thousand 
reactive proteins. Many of these proteins had lower signal intensi-
ties than type I IFN and Th17 cytokines and may partly represent 
a physiological (i.e., non-pathological) autoimmunity in the 
patients, similarly to natural autoantibodies in healthy individu-
als. However, in contrast to the genes activated by Aire in mTECs, 
only the minority was tissue-restricted proteins as we found many 
of the targets expressed in cell types with shared presence in lym-
phoid organs. Our study is in contrast to previous report (15), 
which identified only two novel targets (PDILT and MAGE-B2), 
also detected by our screening here, and with a key observation 
that autoimmunity in APECED preferentially targets molecules 
with restricted tissue expression profiles. The discrepancy may 
be related to conditions of serum samples, serum dilutions, dif-
ferences in the versions of the Protoarray platforms, screening 
process and data analysis. While the previous study set highly 
stringent criteria considering only antigens that were common to 
the patient group we included the rare patient-specific reactivi-
ties, which to some extent may contain false positives.
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Among tissue-restricted proteins, we found reactivity to 
many CT-As, implying a central role of the thymus in antitumor 
immunity. These included members of MAGE-A, MAGE-B, and 
GAGE families, and in addition sperm-specific proteins, recog-
nized by several (including female) patient sera. By contrast, we 
did not detect reactivities to MAGE-D or MAGE-E, the non-
CT-A members of MAGE protein family (43) that are expressed 
in all tissues. Importantly, the only cell type expressing CT-As 
outside of tumors and testis is mTEC (44), and in agreement 
with our findings of extensive anti-CT-A immunity in APECED, 
Aire-deficient mice confer strong rejection of melanoma by 
thymus-dependent T cell responses (45–47). Furthermore, Aire 
has a dual role in the maintenance of immune tolerance as it also 
drives the development of a subset of regulatory T cells; indeed, 
suppressive Aire-dependent regulatory T cells were recruited to 
tumor sites in a mouse model of prostate cancer (48). Thus, our 
data in human patients highlight the role of AIRE in modulat-
ing immune responses to CT-As with implications for cancer 
immunotherapy.
The repertoire and properties of target autoantigens, which 
represent the collection of proteins without any recognizable rule, 
have been enigmatic. Clearly, the property to become an autoan-
tigen is not a single intrinsic feature but a variable combination 
of protein characteristics. These features may include antigen 
structure, susceptibility to proteolytic cleavage, localization in 
apoptotic blebs, and release into the extracellular space (49). 
Other studies have highlighted structural motifs (50), evolu-
tional conservation (41), posttranslational modifications (39), 
and a pro-inflammatory milieu of tissues (51). Post-translational 
modifications have been associated with various autoimmune 
diseases and include citrullination in rheumatoid arthritis (52), 
deamidation in celiac disease (53) and phosphorylation in 
systemic lupus erythematosus (54). We indeed found enrich-
ment of evolutionarily conserved intracellular phosphoproteins, 
suggesting this posttranslational modification as one key factor 
in eliciting autoantibodies, and that specific protein properties 
contribute to B cell autoimmunity. In parallel to B cell epitopes, 
antigen phosphorylation is widespread and preserved among 
T  cell epitopes on major histocompatibility complex (MHC) 
class I and II (55, 56), and deregulated phosphorylation creates 
tumor-specific neoantigens by affecting the antigenic identity or 
binding to MHC (57).
The high and neutralizing autoantibody titers to pro-inflam-
matory cytokines type I IFNs, IL-17A, IL-17F, and IL-22 implicate 
the inflammatory environment in the generation of the APECED 
autoantigen repertoire, although their scarcity in Aire-deficient 
mice (29) remains unexplained. Second, as high titer neutralizing 
anti-IFNα and anti-IFNω autoantibodies are present in AIRE-
deficient thymoma and in recently described RAG-hypomorphic 
patients who lack AIRE expression (58), this strongly suggests the 
impairment of AIRE-dependent thymic tolerance in the devel-
opment of anti-cytokine antibodies in humans. However, type I 
IFNs and Th17 cytokines are not restricted in their expression to 
mTECs; likewise the expression of GAD1, steroidogenic enzymes 
CYP17A1 and CYP21A2, and thyroglobulin is present in other 
thymic cells and they have no correlation with AIRE expression 
(59–61), in contrast to insulin and the alpha-subunit of AChR (59). 
In AIRE-deficient thymoma samples, some APECED autoanti-
gens are expectedly under-expressed, but many are not, including 
several adrenocortical, gonadal and neuro-ectodermal targets 
(60, 62). Hence, other cell types in the thymus should contribute 
to the negative selection of autoreactive T  cells. Thus, other 
mechanisms should be considered, in addition to the role of AIRE 
in shaping negative selection by upregulating the expression of 
TR antigens. Indeed, the very early onset of clinical symptoms in 
APECED patients have suggested that AIRE deficiency may cre-
ate an actively immunizing tissue environment where tolerance 
of AIRE-independent antigens is broken (63).
Despite the fact that approximately 90% of the overall group 
of autoantigens were not tissue-restricted, the correlation of 
TR-specific subset with mature mTEC population and Aire 
dependency was strikingly strong. Thus, our results demonstrate 
two distinct subgroups of autoantigens; first, the smaller sub-
group, which consists of approximately 10% of autoantigens, is 
expressed in specific tissues, and of which many are expressed 
in mTECs under Aire regulation. The breakdown of tolerance 
to these APECED autoantigens is likely driven by their lack of 
expression in the thymus, causing the defect in negative selection 
of autoreactive thymocytes. The characteristic members of this 
group are GIF, CYP2A7, LCN1, as well as GAD2, the expression 
of which followed AIRE’s expression pattern in thymomas (62), 
and conceivably CT-As, for which AIRE-dependency in human 
thymus remains unknown. By contrast, the second subgroup of 
NTR autoantigens is associated with intracellular phosphopro-
teins, expressed in multiple tissues with enrichment in lymphoid 
tissues (lymph node, spleen, bone marrow, and tonsils), and as 
such represents the mTEC-independent breach of tolerance, 
albeit caused by AIRE mutations. Autoantibodies to these pro-
teins emerge by actions of yet unknown mechanisms associated, 
for example, with apoptotic cell death or by dysfunctional B cell 
tolerance during differentiation in lymphoid tissues. Our find-
ings are supported by RNA-seq analysis of autoantigen-encoding 
genes, which identified a subset of autoantigens, associated with 
autoimmune diseases, to be expressed ubiquitously but enriched 
in immune tissues (64). It should be noted that, in contrast to 
other immune tissues, the thymus was not available via Human 
Protein Atlas (20). Nevertheless, given the proposed hypothesis 
of active autoimmunization in AIRE-deficient thymus, this raises 
intriguing questions of whether the second set of lymphoid 
autoantigens might represent the antigens acquired form apop-
totic thymocytes.
Finally, we identified so far unrevealed clinical associations 
with pernicious anemia, vitiligo, and autoimmune hepatitis. 
These correlations need further studies as well as the analysis 
of the expression of target proteins in corresponding diseased 
organs and tissues. Despite several outstanding correlations 
of clinical disease and specific autoantibodies in APECED, the 
majority of autoantibody reactivities seem not to have relevance 
to specific clinical entities. They can be just a bystander result 
of T cell responses, not necessarily reflecting full-blown autoim-
mune attack or their reactivity may depend on other factors, 
for example, the presence of posttranslational modifications or 
complexes with nucleic acids, which can operate as adjuvants. 
In contrast to single autoantigen responses, our results highlight 
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the overall spread of autoantibody repertoire as a driver for the 
expansion of clinical profiles in APECED. Alternatively, these 
autoantibodies may have unexpected protective roles as we 
recently showed a negative correlation of anti-IFNA antibodies 
with the incidence of T1D (9). The unexpectedly broad APECED 
autoimmunome forms a unique platform for further analysis of 
B  cell autoimmunity toward self-antigens and their correlation 
with clinical manifestations.
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